Zacks Research Issues Positive Estimate for CRSP Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Analysts at Zacks Research boosted their Q2 2025 earnings estimates for shares of CRISPR Therapeutics in a research report issued on Tuesday, May 27th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($1.58) for the quarter, up from their prior estimate of ($1.61). The consensus estimate for CRISPR Therapeutics' current full-year earnings is ($5.16) per share. Zacks Research also issued estimates for CRISPR Therapeutics' Q3 2025 earnings at ($1.36) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($5.76) EPS, Q1 2026 earnings at ($1.56) EPS, Q2 2026 earnings at ($1.59) EPS, Q3 2026 earnings at ($1.33) EPS, Q4 2026 earnings at ($1.18) EPS, FY2026 earnings at ($5.66) EPS, Q1 2027 earnings at ($1.47) EPS and FY2027 earnings at ($4.68) EPS.

Other equities research analysts have also recently issued research reports about the stock. Barclays lowered their target price on shares of CRISPR Therapeutics from $56.00 to $42.00 and set an "equal weight" rating on the stock in a research note on Friday, May 9th. Morgan Stanley lifted their target price on shares of CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an "underweight" rating in a research note on Friday, February 14th. TD Cowen raised shares of CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 target price on the stock in a research note on Wednesday, February 12th. Royal Bank of Canada reduced their price target on CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating on the stock in a report on Wednesday, February 12th. Finally, Stifel Nicolaus reduced their price target on CRISPR Therapeutics from $53.00 to $49.00 and set a "hold" rating on the stock in a report on Thursday, February 13th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have issued a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $71.75.

CRISPR Therapeutics Trading Down 2.0%

CRSP traded down $0.74 on Friday, hitting $36.04. 2,078,440 shares of the company's stock were exchanged, compared to its average volume of 1,709,615. CRISPR Therapeutics has a fifty-two week low of $30.04 and a fifty-two week high of $67.88. The firm has a 50-day moving average price of $36.59 and a 200-day moving average price of $41.43. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of -8.25 and a beta of 1.88.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.27) by ($0.31). CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. During the same quarter last year, the firm posted ($1.43) EPS. The business's revenue was up 71.6% compared to the same quarter last year.

Hedge Funds Weigh In On CRISPR Therapeutics

Several institutional investors have recently bought and sold shares of CRSP. ARK Investment Management LLC grew its position in CRISPR Therapeutics by 19.7% in the 4th quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after acquiring an additional 1,474,439 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in CRISPR Therapeutics by 182.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,952,751 shares of the company's stock valued at $66,452,000 after acquiring an additional 1,262,560 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in CRISPR Therapeutics by 39.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock valued at $150,029,000 after acquiring an additional 1,074,238 shares in the last quarter. Capital International Investors grew its position in shares of CRISPR Therapeutics by 10.3% during the fourth quarter. Capital International Investors now owns 8,743,523 shares of the company's stock worth $344,145,000 after buying an additional 816,789 shares in the last quarter. Finally, Millennium Management LLC grew its position in shares of CRISPR Therapeutics by 6,769.1% during the first quarter. Millennium Management LLC now owns 583,733 shares of the company's stock worth $19,864,000 after buying an additional 575,235 shares in the last quarter. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 2,850 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total value of $120,897.00. Following the completion of the transaction, the general counsel now directly owns 77,530 shares of the company's stock, valued at $3,288,822.60. The trade was a 3.55% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Julianne Bruno sold 1,198 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $50,819.16. Following the completion of the transaction, the chief operating officer now directly owns 8,263 shares of the company's stock, valued at approximately $350,516.46. This represents a 12.66% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 17,953 shares of company stock worth $736,087. Company insiders own 4.10% of the company's stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.